Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults with cerebrovascular disease: clinical and cost-effectiveness analyses
Banerjee S, Brown A, Hutton B, McGahan L, Asakawa K, Clark M, Severn M, Cox JL, Sharma M
Record ID 32007000763
English
Authors' recommendations:
The estimates of effects with clopidogrel, ticlopidine, and dipyridamole relative to ASA suggest that the therapeutic choice with optimal direct health effects is unclear.The economic analysis found that for patients who were a mean age of 60 years at the time of their initial stroke, ASA is the most cost-effective treatment option for the secondary preventionof recurrent stroke. For patients in this age group who do not tolerate ASA, ASA-ERDP may be a cost-effective alternative. For patients aged 70 years or more at the time of their initial stroke,ASA-ERDP was found to be the most cost-effective treatment option. These conclusions assume a willingness-to-pay threshold of $50,000 per QALY, and are subject to the limitations of theanalysis.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/947
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Atherosclerosis
- Platelet Aggregation Inhibitors
- Recurrence
- Ticlopidine
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.